Understanding connective tissue development and disease with PDGFR-driven.....

通过 PDGFR 驱动了解结缔组织发育和疾病......

基本信息

  • 批准号:
    8466513
  • 负责人:
  • 金额:
    $ 34.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY (See instructions): Homologous recombination is the only error-free system to repair DNA double-strand breaks. In meiosis, homologous recombination also provides temporal association between pairs of homologous chromosomes allowing their orderly segregation to opposite poles of dividing nuclei. This has a direct impact on faithful haploidization of a genome versus generation of aneuploidy. Indeed, failure of proper homologous chromosome segregation leads to infertility and severe aneuploid-based birth defects such as Down, Klinefelter, Edwards and Turner syndromes. At the center of the homologous recombination pathway is the step of strand invasion catalyzed by the ubiquitous Rad51 and the meiotic specific Dmcl recombinases. The proper functions of the recombinases require interaction with accessory proteins. Our central hypothesis is that two accessory proteins, Hop2 and Mndl, are essential for normal progression of homologous recombination and homologous chromosome segregation in mammalian meiosis. In part this may be explained by Hop2 and Mndl forming a heterodimer that stimulates strand invasion promoted by Dmcl and Rad51. In this proposal, we will use genetic and biochemical approaches to test this hypothesis and address fundamental questions about Mndl and Hop2 in higher eukaryotes: what are the structural determinants of the Hop2/Mnd1-Dmc1/Rad51 cooperation, and when and how do Mndl and Hop2 regulate the progression of homologous recombination in mammalian meiotic cells? Additionally, an important goal is to determine whether Hop2 by itself can function as a recombinase. If confirmed, our results will position Hop2 as the only ATP-independent meiotic recombinase and define a new pathway of DSB repair distinct from those promoted by Dmcl and Rad51. Through defining the roles of accessory proteins, the broader implication of our studies is to understand the contribution of homologous recombination in preventing homologous chromosome segregation defects leading to infertility and aneuploidy in humans.
项目总结(见说明): 同源重组是唯一无错误的DNA双链断裂修复系统。在减数分裂中,同源重组也提供了同源染色体对之间的时间关联,允许它们有序地分离到分裂核的相反两极。这对基因组的忠实单倍化与非整倍体的产生具有直接影响。事实上,正确的同源染色体分离的失败导致不育和严重的非整倍体为基础的出生缺陷,如唐氏综合征,克兰费尔特,爱德华兹和特纳综合征。同源重组途径的中心是由普遍存在的Rad 51和减数分裂特异性Dmcl重组酶催化的链侵入步骤。重组酶的正常功能需要与辅助蛋白相互作用。我们的中心假设是,两个辅助蛋白,Hop 2和Mndl,是必不可少的同源重组和同源染色体分离在哺乳动物减数分裂的正常进展。在某种程度上,这可以通过Hop 2和Mndl形成刺激由Dmcl和Rad 51促进的链侵入的异二聚体来解释。在这项提案中,我们将使用遗传和生物化学的方法来测试这一假设,并解决有关Mndl和Hop 2在高等真核生物的基本问题:什么是Hop 2/Mnd 1-Dmc 1/Rad 51合作的结构决定因素,以及何时以及如何Mndl和Hop 2调节哺乳动物减数分裂细胞中同源重组的进展?此外,一个重要的目标是确定Hop 2本身是否可以作为重组酶发挥作用。如果得到证实,我们的研究结果将Hop 2定位为唯一的ATP-独立的减数分裂重组酶,并定义一个新的DSB修复途径,不同于Dmcl和Rad 51促进的DSB修复途径。通过定义辅助蛋白的作用,我们的研究的更广泛的意义是了解同源重组在防止同源染色体分离缺陷导致人类不育和非整倍体的贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lorin Olson其他文献

Lorin Olson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lorin Olson', 18)}}的其他基金

Understanding connective tissue development and disease with PDGFR-driven.....
通过 PDGFR 驱动了解结缔组织发育和疾病......
  • 批准号:
    9234553
  • 财政年份:
  • 资助金额:
    $ 34.44万
  • 项目类别:
Understanding connective tissue development and disease with PDGFR-driven.....
通过 PDGFR 驱动了解结缔组织发育和疾病......
  • 批准号:
    9015456
  • 财政年份:
  • 资助金额:
    $ 34.44万
  • 项目类别:

相似海外基金

Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
  • 批准号:
    10887038
  • 财政年份:
    2023
  • 资助金额:
    $ 34.44万
  • 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
  • 批准号:
    10877239
  • 财政年份:
    2023
  • 资助金额:
    $ 34.44万
  • 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
  • 批准号:
    MR/X007979/1
  • 财政年份:
    2023
  • 资助金额:
    $ 34.44万
  • 项目类别:
    Research Grant
Cell competition, aneuploidy, and aging
细胞竞争、非整倍性和衰老
  • 批准号:
    10648670
  • 财政年份:
    2023
  • 资助金额:
    $ 34.44万
  • 项目类别:
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
  • 批准号:
    10735074
  • 财政年份:
    2023
  • 资助金额:
    $ 34.44万
  • 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
  • 批准号:
    10538074
  • 财政年份:
    2022
  • 资助金额:
    $ 34.44万
  • 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
  • 批准号:
    10537275
  • 财政年份:
    2022
  • 资助金额:
    $ 34.44万
  • 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
  • 批准号:
    10661533
  • 财政年份:
    2022
  • 资助金额:
    $ 34.44万
  • 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
  • 批准号:
    10467260
  • 财政年份:
    2022
  • 资助金额:
    $ 34.44万
  • 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
  • 批准号:
    10366610
  • 财政年份:
    2022
  • 资助金额:
    $ 34.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了